Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection

Clinical and Experimental Immunology

Volumn 142, Issue 2, 2005, Pages 354-361

  Burton, C T ^a   Nelson, M R ^a   Hay, P ^b   Gazzard, B G ^a   Gotch, F M ^a   Imami, N ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Chronic HIV 1 infection; HAART; Pro viral DNA; Therapy interruption

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; VIRUS DNA;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE COUNT; PATIENT CARE; PLASMA; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; TIME; TOXICITY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 27644575510     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02918.x     Document Type: Article

References (24)

1. Mocroft A, Devereux H, Kinloch-de-Loes S et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population: Royal Free Centre for HIV Medicine. AIDS 2000; 14:1545-52.
2. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-60.
3. Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-8.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
5. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-3.
6. Lowe SH, Prins JM, Lange JM. Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I. established and potential determinants of virological outcome. Neth J Medical 2004; 62:424-40.
7. Li X, Margolick JB, Conover CS et al. Interruption and discontinuation of highly active antiretroviral therapy in the multi-center AIDS cohort study. J Acquir Immune Defic Syndr 2005; 38:320-8.
8. Pillay D, Taylor S, Richman DD. Incidence and impact of resistance against approved antiretroviral drugs. Rev Med 2000; 10:231-53.
9. Garcia F, Plana M, Ortiz GM et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15:F29-F40.
10. Garcia F, Plana M, Vidai C et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13:F79-F86.
11. Davey RT Jr, Bhat N, Yoder C et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96:15109-14.
12. Cohen J. HIV suppressed long after treatment. Science 1997; 277:1927.
13. Lisziewicz J, Lori F. Structured treatment interruptions in HIV/AIDS therapy. Microbes Infect 2002; 4:207-14.
14. Finzi D, Hermankova M, Pierson T et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
15. Chun TW, Stuyver L, Mizell SB et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-7.
16. Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2005; 191:348-57.
17. Pires A, Hardy G, Gazzard B, Gotch F, Imami N. Initiation of Anti-retroviral Therapy During Recent HIV-1 Infection Results in Lower Residual Viral Reservoirs. J Acquir Immune Defic Syndr 2004; 36:783-90.
18. Sullivan AK, Burton CT, Nelson MR et al. Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Scand J Immunol 2003; 57:600-7.
19. Fessel WJ, Krowka JF, Sheppard HW et al. Dissociation of immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 23:314-20.
20. Imami N, Hardy GA, Nelson MR et al. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy. Clin Exp Immunol 1999; 118:78-86.
21. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ. Rapid effector function in CD8+ memory T cells. J Exp Med 1997; 186:859-65.
22. Lambotte O, Chaix ML, Gubler B et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18:1147-58.
23. Katlama C, Dominguez S, Gourlain K et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-26.
24. Douek DC, Brenchley JM, Betts MR et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-8.